Download
the CAR T
discussion tool

HOW YESCARTA WORKS

It starts with your own T cells

Your immune system has different types of white blood cells, all working together to keep you healthy. One type of white blood cell, called the T cell, has the very important job of finding and destroying things that can harm your body, like infection or cancer. In some cases, however, your T cells aren't able to recognize cancer cells.

T cells T cells T cells
Yescarta CAR T cells T cells
Yescarta CAR T cells T cells
Yescarta CAR T cells T cells

YESCARTA helps your T cells do the job they were meant to do

YESCARTA is a therapy where your own T cells are modified in a way that can improve their ability to recognize and destroy cancer cells. YESCARTA is a type of immunotherapy known as CAR T, or Chimeric Antigen Receptor T-cell therapy.

YESCARTA CAN HELP YOU ACHIEVE REMISSION IN AS LITTLE AS 1 MONTH AFTER TREATMENT

In a clinical study, YESCARTA was shown to help the majority of patients with non-Hodgkin lymphoma who had experienced other treatment failures:

  • 51% of patients achieved complete remission, seeing a disappearance of all signs of cancer. This does not always mean the cancer has been cured
  • 21% of patients experienced partial remission, experiencing a decrease in the amount of cancer within the body

Patients were followed for a minimum of ~9 months after receiving YESCARTA to gather these results. Many of these patients responded to treatment in as little as 1 month (range 0.8–6.2 months)

72% of patients saw a meaningful decrease in signs of cancer
ONGOING CLINICAL STUDY RESULTS

AT A 3-YEAR FOLLOW-UP, NEARLY HALF OF PATIENTS TREATED WITH YESCARTA WERE STILL LIVING

The YESCARTA clinical study also evaluated how long patients would live after receiving treatment. At the 3-year follow-up, 47% of patients treated with YESCARTA were still alive. Not all of these patients stayed in remission.